Opus Genetics has completed a Type B Regenerative Medicine Advanced Therapy (RMAT) meeting with the US Food and Drug ...
Zacks Investment Research on MSN
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to earnings of $0.31 per share a ...
Large-scale analyses connect genetic risk factors in lupus with ACR-82 clinical manifestations, suggesting genetic risk ...
Zacks Investment Research on MSN
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.44 per share a year ago. These ...
HLA class I alleles, one known and one newly identified, are linked to allopurinol-induced severe cutaneous adverse reactions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback